Novo Nordisk (NVO) reported lower-than-expected second-quarter 2024 results. The company’s earnings of 65 cents per American Depositary Receipt missed the Zacks Consensus Estimate of 71 cents. The miss can be attributed to significantly higher operational costs during the quarter.Revenues of $9.82 billion, despite a year-over-year increase, missed the Zacks Consensus Estimate of $9.91 billion.Novo Nordisk expects its sales to grow in 2024. However, the company has lowered its guidance for operating profit g ...